Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
In one corner, we have Epogen, sold by entrenched leader and biotech powerhouse Amgen (NAS: AMGN) . In the other is Affymax (NAS: AFFY) , backed by Japanese giant Takeda Pharmaceutical, and their new
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.
Click to skip ahead and jump to the 5 Best Large Biotech Stocks to Buy Now. ... The company’s top-selling drugs between 2017 to 2019 were Enbrel, Neulasta, Prolia, XGEVA, Aranesp, KYPROLIS ...
Click to skip ahead and jump to the 5 Best Large Biotech Stocks to Buy Now. Biotech companies are research science-driven companies focusing on novel drug development and clinical research with ...
In 1983 his team successfully established the gene coding for it [2] and recombinant human erythropoietin was approved by the US FDA in June 1989 [3] with the generic name epoetin alpha, tradename Epogen. [4] [5] Lin was also engaged in developing novel pharmaceutics and studying their molecular mechanisms.
Here's a closer look at the road ahead of Geron Corp to see if it's a good stock to buy now. ... caused by MDS for patients who don't respond to drugs like Amgen's Epogen and other red blood cell ...
In response to these advisories, the FDA released a Public Health Advisory [14] on 9 March 2007, and a clinical alert [15] for doctors on 16 February 2007, about the use of erythropoeisis-stimulating agents (ESAs) such as epoetin alfa (marketed as Epogen) and darbepoetin alfa. The advisory recommended caution in using these agents in cancer ...